SOURCE-LINKED STUDY SUMMARY
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized comparison of weekly semaglutide 2.4 mg with daily liraglutide 3.0 mg for weight loss, alongside diet and physical activity.
- Who / model studied
- 338 adults with overweight or obesity and no diabetes, followed for 68 weeks; the trial also included placebo groups.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary comparison showed average weight loss of 15.8% with semaglutide versus 6.4% with liraglutide. For a confirmatory secondary outcome, 38.5% versus 6.0% lost at least 20%. Digestive adverse events occurred in 84.1% versus 82.7%. Treatment discontinuation for any reason was 13.5% versus 27.6%.
- Limitations & context
- The active-drug comparison was unblinded. Semaglutide allowed dose reduction for intolerance; liraglutide required stopping, with an option to restart.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2021.23619